Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
Healthcare
$18.20 +0.40%
+$0.09 today
- Market cap
- $2.92B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
52W Low $12.58High $24.65
Volume 1.27M
Average 1.84M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$555.34M
FY 2025 · Annual
Net Income
-$512.54M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| 121.52M | 125.53M | 137.37M | 164.47M | 175.46M | |
| 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
DNLI Earnings Waterfall · TTM
NASDAQ:DNLI · Revenue to Net Income
Key Ratios
EPS$-2.84
Gross Margin24.4%
Net Margin-884.8%
P/E Ratio-6.7
P/S Ratio334.2
Analysis
$3.6M of revenue converted into -$511.5M of net income for the selected period. Gross margin is 24.4% and net margin is -884.8%, showing how much revenue survives after costs and taxes. EPS is $-2.84, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
How much revenue does DNLI generate?
Denali Therapeutics Inc. (DNLI) reported $0.00 of revenue in fiscal 2025.
Is DNLI profitable?
Denali Therapeutics Inc. (DNLI) reported -$512.54M of net income.
Continue the stock analysis
Jump to another research area for this company.